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Abstract
Purpose: Pancreatic cancer is an aggressive malignancy with characteristic metastatic course of disease and resistance to
conventional chemo-radiotherapy. RLIP76 is a multi-functional cell membrane protein that functions as a major mercapturic
acid pathway transporter as well as key regulator of receptor-ligand complexes. In this regard, we investigated the
significance of targeting RLIP76 on PI3K/Akt pathway and mechanisms regulating response to chemo-radiotherapy.
Research Design and Methods: Cell survival was assessed by MTT and colony forming assays. Cellular levels of proteins and
phosphorylation was determined by Western blot analyses. The impact on apoptosis was determined by TUNEL assay. The
anti-cancer effects of RLIP76 targeted interventions in vivo were determined using mice xenograft model of the pancreatic
cancer. The regulation of doxorubicin transport and radiation sensitivity were determined by transport studies and colony
forming assays, respectively.
Results: Our current studies reveal an encompassing model for the role of RLIP76 in regulating the levels of fundamental
proteins like PI3K, Akt, E-cadherin, CDK4, Bcl2 and PCNA which are of specific importance in the signal transduction from
critical upstream signaling cascades that determine the proliferation, apoptosis and differentiation of pancreatic cancer
cells. RLIP76 depletion also caused marked and sustained regression of established human BxPC-3 pancreatic cancer tumors
in nude mouse xenograft model. RLIP76 turned out to be a major regulator of drug transport along with contributing to the
radiation resistance in pancreatic cancer.
Conclusions/Significance: RLIP76 represents a mechanistically significant target for developing effective interventions in
aggressive and refractory pancreatic cancers.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
deaths among men and women [1]. Approximately 95% of
malignant tumors within the pancreas arise from the exocrine
tissue. Among pancreatic exocrine malignancies, 80% to 90% are
ductal adenocarcinomas [2,3]. Fewer than 20% of patients with
pancreatic cancer have disease that is macroscopically confined to
the pancreas at diagnosis with the rest of the patients presenting
with locally advanced and distant visceral metastases, usually
involving the liver [4]. Pancreatic cancers possess multiple
aberrations in the cellular signaling cascades and are character-
istically known for their invasive phenotype and refractoriness to
conventional modes of therapy. The treatment of pancreatic
cancer is frequently met with disappointing outcomes due to the
development of resistance to therapy consequent to activation of a
number of survival promoting proteins which transduce signals
from extracellular signaling molecules such as epidermal growth
factor (EGF), transforming growth factor (TGF), or insulin-like
growth factors (IGF1) [5,6]. Molecular studies have also
characterized the mutations of K-ras oncogene in 80% or more
of ductal adenocarcinomas [7]. The PI3K/Akt pathway plays a
significant role in signal transduction from upstream growth factor
receptors as well as oncogenic K-ras [8–12]. PI3K/Akt signaling
also represents a potent and fundamental axis of signal relay that
determines the basal survival and resistance to the apoptotic effects
of chemo-radiotherapy in a variety of cancers, which makes
PI3K/Akt pathway a central focus of mechanistic investigations in
pancreatic cancer [13,14]. Currently, there is no effective
treatment for pancreatic cancer and conventional chemo-radio-
therapy has shown very limited success in improving patient
survival. The overall survival rate of pancreatic cancer patients is
,5%. Hence, the investigation of the mechanisms of action of
novel targets which can regulate the molecular changes that drive
the pancreatic cancer survival and refractoriness to therapy will
facilitate the development of effective interventions for pancreatic
cancer [4,15].
Mercapturic acid pathway plays a critical role in regulating the
cellular antioxidant potential and resistance to chemo-radiother-
apy [16]. Glutathione (GSH) is a sulfur containing small molecule
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stimuli that induce cell death [17]. During the first step of
mercapturic acid pathway, the cellular glutathione S-transferases
(GSTs) catalyze the conjugation of administered chemotherapy
drugs and products of lipid peroxidation, induced consequent to
radiotherapy, with GSH to form glutathione-conjugates (GS-Es)
[18]. The GS-Es are still toxic to the cells and need to be effluxed
out of cells in order to protect the cells from cell death. During the
second step of mercapturic acid pathway, the GS-Es are effluxed
out of cells and this process is mediated by energy-dependent
transport pumps present in the cell membranes [19]. In our
extensive previously published studies, we have shown that
RLIP76 is a primary mercapturic acid pathway transporter that
removes GS-Es resulting from products of lipid peroxidation and
chemotherapy drugs from the cells. This function of RLIP76 is
more important for cancer cells as compared with normal cells as
depletion of RLIP76 does not kill normal cells, but is very effective
in killing cancer cells of nearly all types [20–24].
Our recently published studies indicate that RLIP76 is also a
stress-responsive GS-E transporter required for clathrin-dependent
endocytosis (CDE), which is required for regulation of receptor-
ligand signaling at the cell membrane receptors [25]. In the
context of striking chemo-radiotherapy resistance of pancreatic
cancers and the fundamental role of RLIP76 as an important
mercapturic acid pathway transporter that is essential for survival
and therapy resistance in cancers, we investigated the role of
RLIP76 in regulating the critical signaling proteins involved in
relaying the inputs from multiple upstream survival pathways and
mechanisms contributing to chemo-radiotherapy resistance in
pancreatic cancer.
Materials and Methods
Materials
Doxorubicin (DOX, adriamycin) was obtained from Adria
Laboratories (Columbus, OH).
3H-GSH (3,000 Ci/mmol) was
purchased from Pharmacia Biotech (Piscataway, NJ).
14C-DOX
(specific activity 44.8 Ci/mmol) was purchased from NEN Life
Sciences (Boston, MA). Polyclonal rabbit-anti-human rec-RLIP76
IgG as well as pre-immune IgG were prepared and purified as
described previously [26,27]. MRP (N19; cat # sc7774), Pgp (C19;
cat # sc1517), Akt (cat # Sc8312), GAPDH (cat # sc32233), Bcl2
(cat # sc509), Bim (cat # sc11425), and cyclin B1 (cat # sc595)
antibodies were obtained from Santa Cruz Biotechnology
(Columbus, OH). pAkt (S
473; cat # 05-736) antibody was
procured from Upstate Cell Signaling (Lake Placid, NY).
Antibodies against PI3K (cat # 4292S), pPI3K (Y
458; cat #
4228), and PCNA (cat # 2586S) were from Cell Signaling
Technologies (Danvers, MA). E-cadherin (cat # C3621), b-actin
(cat # A5441), and cdk4 (cat # DCS-35) antibodies were from
Sigma-Aldrich Corp. (St. Louis, MO.) and Neomarkers (Fremont,
CA), respectively. TUNEL fluorescence detection kit was pur-
chased from Promega (Madison, WI). DNP-SG was synthesized
from CDNB and GSH according to the method described by us
previously [28]. All animal experiments were carried out in
accordance with the Institutional Animal Care and Use Commit-
tee (IACUC) approved protocol. RLIP76 antisense was purchased
from Biosynthesis, Inc., (Lewisville, TX) [22], and RLIP76 siRNA
was purchased from Dharmacon Research (Lafayette, CO), as
described previously [29].
Animals
Hsd: Athymic nude nu/nu mice were obtained from Harlan,
Indianapolis, IN. Animals were maintained at the Beckman
Research Institute, City of Hope National Medical Center,
Duarte, CA. All animal experiments were carried out in
accordance with an approved protocol (# 11016) by Beckman
Research Institute, City of Hope National Medical Center
Institutional Animal Care and Use Committee (IACUC).
Cell Lines and Cultures
Human umbilical vascular endothelial cells (HUVEC) were
kindly provided by Dr. Fiemu Nwariaku, University of Texas
Southwestern Medical Center, Dallas, TX, as described previously
(22–24), and cultured at 37uC in a humidified atmosphere of 5%
CO2 in EGM-2 bullet kit medium supplemented with 10% (v/v)
heat-inactivated FBS and 1% (v/v) Pen-Strep (P/S) solution.
Human pancreatic cancer (BxPC-3 and Panc-1) cell lines were
purchased from American Type Culture Collection, Manassas,
VA, and cultured at 37uC in a humidified atmosphere of 5% CO2
in MEBM and RPMI-1640 medium supplemented with 10% (v/v)
heat-inactivated FBS, 1% (v/v), Pen-Strep (P/S) solution, 2 mM
L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L
glucose, and 1.5 g/L sodium bicarbonate. All cells were tested for
Mycoplasma once every 3 months.
MTT cell viability assay
Cell number/ml in an aliquot of cells growing in log phase was
determined by counting trypan blue excluding cells in a
hemocytometer and 20,000 cells were plated into each well of
96-well flat-bottomed micro-titer plates. After 12 h incubation at
37uC, medium containing either pre-immune IgG or anti-RLIP76
IgG (40 mg/ml final concentration) were added to the cells. After
24–48 h incubation, 20 ml of 5 mg/ml MTT was introduced to
each well and incubated for 2 h of exposure. The plates were
centrifuged and medium was decanted. Cells were subsequently
dissolved in 100 ml DMSO with gentle shaking for 2 h at room
temperature, followed by measurement of OD570 nm [30]. Eight
replicate wells were used in each point in each of three separate
measurements. Measured absorbance values were directly linked
with a spreadsheet for calculation of IC50, defined as the drug
concentration that reduced formazan formation by 50%. Deple-
tion of RLIP76 expression in cells by RLIP76 siRNA and RLIP76
antisense were measured as follows: cells were incubated for 3 h
with 0–2 mg/well of either RLIP76 siRNA using Transmessenger
Transfection Reagent (Qiagen) or RLIP76 anti-sense using
Maxfect transfection reagent (MoleculA) according to the
manufacturer provided protocols.
Cloning, prokaryotic expression, and purification of
RLIP76
Purified RLIP76 protein (1965 bp; 655 aa) was obtained from
E. coli BL21(DE3) expressing the pET30a(+) plasmid containing
full-length cDNA corresponding to the sequence of RLIP76. The
purification was carried out using DNPSG-affinity resin as
described previously and purity was confirmed by Western blot
analyses [26,31].
Functional reconstitution of purified rec-RLIP76 into
artificial liposomes and transport studies
Purified RLIP76 was dialyzed against reconstitution buffer
(10 mM Tris-HCl, pH 7.4, 2 mM MgCl2, 1 mM EGTA,
100 mM KCl, 40 mM sucrose, 2.8 mM BME, 0.05 mM BHT,
and 0.025% polidocanol). An aqueous emulsion of soybean
asolectin (40 mg/ml) and cholesterol (10 mg/ml) was prepared
in the reconstitution buffer by sonication and 0.1 ml of this
mixture was added to 0.9 ml aliquot of dialyzed and purified rec-
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30 sec. Vesiculation was initiated by the addition of 200 mg SM-2
Bio-beads pre-equilibrated in the reconstitution buffer without
polidocanol. Vesiculation was carried out for 4 h at 4uC, the SM-2
Bio-beads were removed by centrifugation and the vesicles
(RLIP76-liposomes) were collected. The collected fraction yields
primarily unilammelar vesicles with median diameter of 0.25 mm
and intravesicular/extravesicular volume ratio of 18 mL/mL.
Control vesicles (control-liposomes) were prepared using an equal
amount of albumin or crude protein from E. coli not expressing
RLIP76. ATP-dependent transport of
14C-DOX and
3H-DNPSG
in the rec-RLIP76 reconstituted proteoliposomes was performed
by rapid filtration technique using the exact protocol described by
us previously where the efficiency of delivery for proteoliposomes
has been established [26].
Preparations of crude membrane fractions for Western
blot analyses
Crude membrane fractions were prepared from the normal and
cancer cell lines using established procedures as described
previously [22]. Briefly, cells were pelleted and washed with
balanced salt solution (138 mM NaCl, 5 mM KCl, 0.3 mM
KH2PO4, 0.3 mM Na2HPO4, 4 mM NaHCO3, and 5.6 mM
glucose, pH 7.4) three times. Washed cells were lysed in 10 mM
Tris-HCl, pH 7.4, containing 1.4 mM BME, 0.1 mM PMSF,
0.05 mM BHT, 0.1 mM EDTA and 0.5% (v/v) polidocanol.
Lysates were sonicated three times for 30 sec at 50W and
incubated for 4 h at 4uC with occasional shaking. After
incubation, the resultant preparation was centrifuged at 100,000-
6 g for 60 min at 4uC. The supernatant was collected and
subjected to SDS-PAGE. Levels of RLIP76 protein in normal and
cancer cells was measured by Western blot and ELISA using anti-
RLIP76 IgG as previously described [29,31]. Purified rec-RLIP76
with purity assessed by amino acid composition analysis was used
to generate calibration curves.
Transport studies in IOVs
Crude membrane vesicles (inside-out vesicles, IOV) were
prepared from the normal (HUVEC) and malignant (BxPC-3
and Panc-1) cell lines using established procedures as described by
us for the K562 cells [26]. Transport studies of DOX and DNP-
SG in IOVs were performed by the method as described
previously [26]. IOVs were separately coated with 40 mg/ml final
concentration of either anti-RLIP76 IgG, anti-MRP1 IgG, or anti-
Pgp IgG and used to measure the ATP-dependent uptake of
14C-
DOX. ATP-dependent uptake of
14C-DOX was determined by
subtracting the radio-activity (cpm) of the controls without ATP
from that of the experimental groups containing ATP. The
transport of DOX was calculated in terms of pmol/min/mg IOV
protein. The transport of
3H-DNP-SG was measured in a similar
manner.
Tumor xenografts model
Hsd: Athymic nude nu/nu mice were obtained from Harlan,
Indianapolis, IN. All animal experiments were carried out in
accordance with a protocol approved by the Institutional Animal
Care and Use Committee (IACUC). Thirty-six 10-weeks-old mice
were divided into six groups of 6 animals (treated with pre-
immune serum, scrambled siRNA, scrambled antisense, RLIP76
antibodies, RLIP76 siRNA and RLIP76 antisense DNA). All 36
animals were injected with 2610
6 human pancreatic cancer cells
(BxPC-3) suspensions in 100 ml of PBS, subcutaneously. Animals
were examined daily for signs of tumor growth. Treatment was
administered when the tumor surface area exceeded ,42 mm
2
(day 47 after tumor cell injection, i.e. day 1 for treatment).
Treatment consisted of 200 mg of either RLIP76 antibodies,
RLIP76 siRNA or RLIP76 antisense in 100 ml PBS. Control
groups were treated with 200 mg/100 ml pre-immune serum,
scrambled siRNA and scrambled antisense. Tumors were
measured in two dimensions by calipers.
Colony formation assay
Cells (0.1610
6 cells/500 mL) were incubated with scrambled
antisense and RLIP76 antisense (10 mg/ml final concentration) for
24 h. After 24 h, aliquots of 50 and 100 mL of were further
incubated in 60 mm size Petri dishes, separately, in a total volume
of 4 ml medium to in each Petri dish. For irradiation experiments,
control and RLIP76-proteoliposomes (50 mg/ml final concentra-
tion, 24 h) treated cells were irradiated at 100, 200, 500 and 1000
cGY using Varian Clinac 2100C Linear Accelerator with 6 MeV
photon beam. After 7 days, adherent colonies were fixed, stained
with 0.5% methylene blue for 30 min., and colonies were counted
using Innotech Alpha Imager HP [32].
Effect of RLIP76 antisense on apoptosis by TUNEL assay
Cells (,1610
6) were grown on the cover slips and treated with
scrambled antisense and RLIP76 antisense (10 mg/ml final
concentration) in Maxfect transfection reagent (MoleculA).
Apoptosis was determined by the labeling of DNA fragments with
terminal deoxynucleotidyl-transferase dUTP nick-end labeling
(TUNEL) assay using Promega apoptosis detection system
according to the protocol provided by manufacturer [33].
Statistical Analysis
All data were evaluated with a two-tailed unpaired student’s t
test or compared by one-way ANOVA and are expressed as the
mean 6 SD. For in vivo studies, drug-treatment values were
compared with the control vehicle-treatment values. A p
value,0.05 was considered statistically significant.
Results
Expression of RLIP76 in pancreatic cancer cells
Western blot analyses of the membrane protein extracts from
human normal and pancreatic cancer cells indicated the presence
of relatively larger amounts of RLIP76 in pancreatic cancer cells
compared to normal cells (Fig. 1A). Following the characteriza-
tion of enhanced expression of RLIP76, we further investigated
the effect of RLIP76 inhibition or depletion in pancreatic cancer
cells. The results from assessing RLIP76 protein levels as presented
in Table 1 indicate the amounts of total crude membrane
proteins obtained from 10
8 cells in log-phase of growth. RLIP76
protein represented 1262 mg/10
8 normal cells and ,4063 mg/
10
8 pancreatic cancer cells, respectively (0.19% and ,0.61% of
the total detergent soluble protein from the membranes of normal
and pancreatic cancer cells, respectively). The expression of
RLIP76 in pancreatic cancer cells was in comparable range
relative to results from various other cell lines in our previous
studies [22,24,29].
RLIP76 inhibition or depletion causes cytotoxicity in
pancreatic cancer cells
The initial cytotoxic effects of RLIP76 inhibition in pancreatic
cancer cells were assessed by RLIP76 inhibition using anti-RLIP76
IgG and RLIP76 depletion using RLIP76 siRNA or RLIP76
phosphorothioate antisense by an established MTT cell survival
Novel Strategy for Targeting Pancreatic Cancer
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obtained from the pre-immune serum was used as control. Anti-
RLIP76 IgG used in these experiments was previously shown by
Ouchterlony double immuno-diffusion assay to be non-cross-
reactive with any other proteins including Pgp or MRP [31]. Cells
were treated with pre-immune IgG, scrambled siRNA, scrambled
antisense, anti-RLIP76 IgG, RLIP76 siRNA or RLIP76 antisense
for 24 h. The cytoxicity of all three RLIP76 targeting agents,
RLIP76 siRNA, antibody and antisense, was preferentially
directed towards the malignant cells as compared with the non-
malignant HUVEC cells, which was similar to our observations
with other malignant (lung, melanoma, kidney, prostate) and non-
malignant cell lines [22,24,29,34]. In contrast with the previous
results seen with lung or colon cancers (in which all three
modalities gave similar results), RLIP76 antisense was significantly
more effective in killing pancreatic cancer cells than the RLIP76
antibody (Fig. 1B). RLIP76 mediates survival and proliferation of
cancer cells by multiple mechanisms which include enhanced
Figure 1. Comparison of RLIP76 levels in pancreatic cancer cells vs non-malignant cells. Aliquots of crude membrane fractions of
pancreatic cancer cells (BxPC-3 and Panc-1) and normal control cells (HUVEC) containing 100 mg protein were used for SDS-PAGE and Western
blotting. Intensity of the full-length RLIP76 protein (,95 kDa) band was quantified by scanning densitometry using Innotech Alpha Imager HP. b-
actin was used as an internal control (panel A). Impact of anti-RLIP76 IgG, RLIP76 siRNA and RLIP76 antisense on normal and pancreatic cancer cells:
Effect of anti-RLIP76 IgG (40 mg/ml final concentration) on the cell survival was determined by MTT assay [29,30]. Depletion of RLIP76 expression by
RLIP76 siRNA and RLIP76 antisense (each 10 mg/ml final concentration) was done, using Transmessenger Transfection-Reagent-kit (Qiagen), and
Maxfect Transfection-Reagent (Molecula, Inc.), respectively, according to the manufacturer’s instructions. Cell survival was measured by MTT
cytotoxicity assay 48 h after treatment. The values are presented as mean 6 SD from two separate determinations with eight-replicates each (n=16),
black bars, normal HUVEC cells; gray bars, BxPC-3 pancreatic cancer cells (panel B)*p ,0.05, ** p,0.01 compared to respective controls. Effect of
RLIP76 antisense on PI3K and Akt signaling in pancreatic cancer cells: RLIP76 antisense caused inhibition of PI3K/Akt pathway in BxPC-3 and Panc-1
cells. Cells were treated with 10 mg/ml of RLIP76 antisense for 24 h and immune-blotted for pPI3K, PI3K, pAkt, Akt, Bim, Bcl2, cyclin B1 and CDK4. The
same blot was stripped and reprobed for GAPDH to ensure equal protein loading (panel C). Bar diagram shows the quantitation of respective
Western blots. Dotted line represents no significant change as observed with scrambled antisense (panel D).
doi:10.1371/journal.pone.0034582.g001
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regulation of intracellular signaling pathways [19,25,35]. The
enhanced efficacy of RLIP76 antisense was a striking finding
which stimulated further detailed investigation of RLIP76
depletion in regulating the levels of critical intracellular proteins
in pancreatic cancer cells.
RLIP76 antisense down-regulates PI3K/Akt pathway in
pancreatic cancer cells
BxPC-3 and Panc-1 cells were treated with RLIP76 antisense
for 24 h followed by Western blot analyses to study the impact on
critical intracellular proteins (Figs. 1C and D). PI3K/Akt is
constitutively activated in majority of pancreatic tumors [11].
RLIP76 antisense treatment significantly suppressed the phos-
phorylation of PI3K, a common upstream signal signaling node
which tranduces mitogenic signals consequent to cell membrane
receptors like growth factors and integrins. RLIP76 antisense
treatment also significantly reduced the protein levels and
phosphorylation of Akt in both BxPC-3 and Panc-1 cells.
Interestingly, phosphorylation of Akt and PI3K was not detected
in normal HUVEC cells (data not shown), which is consistent with
the general understanding that PI3K or Akt are activated in
transformed cells [36]. The PI3K and Akt represent significant
nodes of signal relay which in turn regulate the critical
downstream targets that are involved in apoptosis, proliferation
and maintaining the phenotype of cancers. The activation of Akt
leads to repression of the expression of E-cadherin [37]. E-
cadherin is considered a marker of normal epithelial phenotype
and loss of E-cadherin is associated with ‘‘Epithelial mesenchymal
transition (EMT)’’ and an aggressive phenotype in cancers [38].
The activation of PI3K leads to further activation of mTOR which
suppresses the expression of pro-apoptotic Bim and favors survival
and proliferation of cancer cells [39]. The enhanced levels of anti-
apoptotic Bcl2 and cyclin dependent kinase 4 (CDK4) have been
shown to mediate resistance to mTOR inhibition [40]. Depletion
of RLIP76 by antisense significantly increased the levels of the pro-
differentiation marker E-cadherin and pro-apoptotic protein Bim
while decreasing the levels of anti-apoptotic protein Bcl2, cyclin B1
and CDK4 in both BxPC3 and Panc-1 pancreatic cancer cells.
Thus, depletion of RLIP76 had a significant impact on critical
mediators of PI3K/Akt signaling axis in pancreatic cancer
(Figs. 1C and D).
Effect of RLIP76 depletion on clonogenic survival and
apoptosis
We further confirmed the impact of RLIP76 depletion on the
proliferative potential and cell survival by assessing the clonogenic
potential and apoptosis in BxPC3 pancreatic cells. RLIP76
antisense treatment caused RLIP76 depletion as detected by
Western blot (Fig. 2A) and inhibited the clonogenic potential as
determined by colony-forming assay (Fig. 2B). The impact of
RLIP76 on apoptosis was assessed by TUNEL assay. The results
of the TUNEL assay showed no detectable apoptosis with
scrambled antisense while RLIP76 antisense caused apoptosis in
the BxPC-3 pancreatic cancer cells. Quantification of red and
green fluorescence by image -J analysis confirmed the qualitative
fluorescent findings that the RLIP76 depletion by antisense was
effective in inducing apoptosis (Fig. 2C).
RLIP76 depletion causes regression of pancreatic cancer
xenografts in nude mice
The above in vitro observations reflecting the anti-neoplastic
effects of RLIP76 depletion were further investigated in vivo mice
xenograft model of pancreatic cancer. Tumor-bearing animals
with established s.c. implanted BxPC3 pancreatic cell tumors
(,42 mm
2) were treated with 200 mg of either RLIP76 antibody,
RLIP76 siRNA or RLIP76 antisense by i.p. injection. Weight gain
was comparable to non-tumor-bearing controls, and no overt-
toxicity was evident. The treatment with RLIP76 antibody,
RLIP76 siRNA or RLIP76 antisense resulted in rapid and
dramatic reductions in tumors (Figs. 3A and B). The RLIP76
antibody, RLIP76 siRNA or RLIP76 antisense treated animals
bearing established s.c. tumors were alive for ,298 days without
any evidence of recurrence. There was uncontrolled growth in all
the control groups treated with pre-immune serum, scrambled
siRNA and scrambled antisense and hence the control groups
were censored by ,49 days (Fig. 4). The efficacy of tumor-volume
reduction was evident from tumor-weights at day 47 after the
beginning of treatment (Fig. 3B). The effectiveness of RLIP76
antisense in depleting tumor RLIP76 in vivo is demonstrated in the
Western blot for RLIP76 from tumor homogenates (Fig. 3B,
inset). Following RLIP76 depletion and inhibition, regression of
tumor implants were seen in all animals, without any overt toxic
effects, or effects on weight gain.
Table 1. RLIP76 protein expression in human normal and pancreatic cancer cells.
Total crude protein RLIP76 protein
(mg/10
8 cells)
mg/10
8 cells %o ft o t a l
crude protein
Nonmalignant
HUVEC (umbilical endothelial) 6.2860.58 1262 0.19
Malignant
BxPC-3 6.7460.72 4263 0.62
Panc-1 6.4660.64 3863 0.59
Cell lines were cultured in respective medium and homogenate was prepared from 10
8 cells. RLIP76 was purified from total crude membrane fraction using DNP-SG
affinity column chromatography and quantified by ELISA [26,29,31]. Values represent mean 6 s.d. from three separate determinations.
doi:10.1371/journal.pone.0034582.t001
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of PI3K/Akt pathway
Following in vivo studies, we further analyzed the levels of PI3K,
Akt and critical downstream signal transducers in resected control
and RLIP76 antisense treated pancreatic tumor tissue lysates by
Western blot analyses (Figs. 3C and D). The phosphorylation of
PI3K and Akt were drastically suppressed by RLIP76 antisense
treatment. The expression levels of Akt, but not PI3K, was also
reduced in the tumors of RLIP76 antisense-treated mice. Next, we
investigated the levels of pro-apoptotic Bim, E-cadherin, cyclin B1,
and CDK4, which are known to play a critical role in regulating
the proliferation, differentiation and apoptosis of pancreatic
tumors [11,37–40]. We observed a striking decrease in the levels
of PCNA, cyclin B1 and CDK4 levels and increase in the levels of
tumor suppressor E-cadherin and pro-apoptotic protein Bim in the
tumor tissue lysates of RLIP76 antisense-treated mice as compared
with controls. These observations confirmed our in vitro findings
that RLIP76 depletion induces potent anti-proliferative and pro-
apoptotic effects in pancreatic cancers.
Assessment of transport activity of RLIP76 in pancreatic
cancer cells
Following the analysis of the role of RLIP76 in regulating
pancreatic cancer survival and apoptosis in vitro and in vivo,w e
further investigated the significance of the transport function of
RLIP76 in regulating therapeutic resistance in pancreatic cancer
cells. We have previously shown that proteo-liposomes reconsti-
tuted with RLIP76 mediate ATP-dependent transport of doxoru-
bicin (DOX) and other drugs [26]. For assessing the transport
activity of RLIP76, we compared the ATP-dependent uptake of
14C-DOX and
3H-DNP-SG in crude membrane in-side-out
vesicles (IOV) prepared separately from the membranes of control
and pancreatic cancer cells (Table 2). Results from the
measurements of ATP-dependent transport of
14C-DOX and
3H-DNPSG revealed greater transport of both substrates in
pancreatic cancer cells reflecting a positive correlation between
RLIP76 expression and transport-activity in pancreatic cancer
cells which had higher levels of RLIP76 (Table 1) compared to
normal cells [
14C-DOX transport (pmol/min/mg protein) - A.
Normal cells: 2864; B. Pancreatic cancer cells: (i) BxPC3: 144612
and (ii) Panc-1: 131610.
3H-DNP-SG transport (pmol/min/mg)-
A. Normal cells: 10168; B. Pancreatic cancer cells: (i) BxPC3:
681648 and (ii) Panc-1: 611652] .
Relative contribution of RLIP76 towards DOX-transport
DOX is a common allocrite transported by RLIP76 [26],
MRP1 [41,42] and MDR1 [43,44]. Hence, we further quantified
the relative contribution of these transporters in the ATP-
dependent transport of
14C-DOX in BxPC-3 cells using an
immunological approach. We have previously shown that anti-
RLIP76 IgG inhibit DOX-transport in IOVs [31]. Likewise,
specific antibodies against MRP and Pgp also inhibit transport-
activity in IOVs [45,46]. We designed experiments in which IOVs
prepared from BxPC-3 pancreatic cancer cells and separately
coated with anti-RLIP76 IgG, anti-MRP1 IgG, or anti-Pgp IgG
were used to measure the ATP-dependent uptake of
14C-DOX.
Based on initial titration experiments, we used 40 mg/ml of each of
the antibodies to inhibit the transport activity of their respective
antigen present in the IOVs used in these experiments. In control
vesicles coated with pre-immune IgG, the transport activity
remained unaffected. Anti-RLIP76 IgG, which recognized only
RLIP76 in crude extracts of BxPC-3 cells, inhibited 6565% of
total DOX-transport in IOVs prepared from BxPC-3 cells. Anti-
MRP IgG also inhibited DOX-transport in a saturable manner,
but the inhibition was less (2464%) as compared to that observed
with anti-RLIP76 IgG. Anti-Pgp IgG had a small but detectable
inhibitory effect on DOX-transport (763%) (Fig. 5A). Impor-
tantly, these results established that RLIP76 accounts for a major
two-third portion of the ATP-dependent transport of DOX in
pancreatic cancer cells.
Figure 2. Effect of RLIP76 antisense on RLIP76 expression and apoptosis. Depletion of RLIP76 by RLIP76 antisense using Western blot
analyses, lane 1 contained standard, lanes 2 and 3, contained crude membrane fraction of pancreatic cancer (BxPC-3) cells 24 h after treatment of
RLIP76 antisense and scrambled antisense, respectively. Results were quantified by scanning densitometry using Innotech Alpha Imager HP. b-actin
was used as an internal control (panel A). Colony-forming efficiency in BxPC-3 cells after treatment of antisense, was performed by staining the cells
with methylene blue and the colonies were counted using Innotech Alpha Imager HP. Values are means 6 S.D. of three separate experiments. ***
p,0.005 compared with no or scrambled antisense treatment (panel B). Apoptosis in BxPC-3 cells by RLIP76 antisense by TUNEL assay, scrambled
antisense (upper panel) and RLIP76 antisense (lower panel) treated cells. Apoptotic cells showed green fluorescence and characteristic of cell
shrinkage. The adjacent bar diagram shows Image J analyses of TUNEL assay representing percentage of TUNEL positive apoptotic cells (green) and
normal live cells (red). * p,0.05 (panel C).
doi:10.1371/journal.pone.0034582.g002
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In our previous studies, we have shown that RLIP76 regulates
the resistance to chemo-radiotherapy by ATP-dependent transport
of products of lipid peroxidation and administered chemotherapy
drugs [19–21,47]. In this regard, we specifically sought to
determine the role of RLIP76 in regulating the levels of
radiation-sensitivity in pancreatic cancer cells. We first determined
the X-irradiation sensitivity of the RLIP76 and control liposome
treated BxPC3 human pancreatic cancer cells in dose-response
studies utilizing 100–1000 cGY single dose X-irradiation, followed
by colony-forming assays. In these studies, pancreatic cancer cells
were loaded with RLIP76 by incubating with RLIP76-liposomes.
Cells pretreated with RLIP76-liposomes were least sensitive to
radiation. At each dose of radiation, the survival was significantly
more when the cells were pretreated with RLIP76-liposomes
before radiation exposure (Fig. 5B). Interestingly, RLIP76
supplementation by liposomes increased the radiation-resistance
to a significantly higher level at higher doses of radiation
compared to low doses of radiation. This finding reinforces that
RLIP76 is essential to particularly survive oxidative stress induced
by higher levels of radiation (Fig. 5C). Thus, the physiological
significance of RLIP76 mediated transport of endogenously
Figure 3. Treatment with RLIP76 antibody, siRNA or antisense causes regression of established BxPC-3 pancreatic cancer
xenografts. For xenografts studies, we used thirty-six 11-weeks-old Hsd: Athymic nude nu/nu mice (Harlan, Indianapolis, IN) randomized 6 animals
each into six groups as follow: 1) pre-immune serum, 2) scrambled siRNA, 3) scrambled anti-sense DNA, 4) RLIP76 antibodies, 5) RLIP76 siRNA and 6)
RLIP76 antisense. All 36 animals were injected with 2610
6 human pancreatic cancer cells (BxPC-3) suspensions in 100 ml of PBS, subcutaneously into
one flank of each nu/nu nude mouse. Animals were examined daily for signs of tumor growth and body weights. When tumors reached a cross-
sectional area of ,42 mm
2 (47 d later), animals were randomized in to treatment groups as indicated in Figure 4. Treatment consisted of 200 mgo f
RLIP76 antibodies, siRNA or antisense in 100 ml PBS. Control groups were treated with 200 mg/100 ml of either pre-immune serum, scrambled siRNA
or scrambled anti-sense DNA. Tumors were measured in two dimensions using calipers. Tumor measurements are presented with all control groups
(pre-immune IgG, scrambled siRNA or antisense) versus all treated groups (anti-RLIP76 IgG, RLIP76 siRNA, or anti-sense) (panel A). Tumor-weight is
reduced at day 47 after the treatment start (panel B) and tumor RLIP76 is depleted by antisense (panel B, inset). Tumors were excised 48 h after
antisense-treatment, weighed, and homogenized, and aliquots containing 100 mg protein from each, were loaded to SDS-PAGE for Western blotting
against anti-RLIP76 IgG (n=3; lanes 1–3, scrambled antisense treated, and lanes 4–6, RLIP76-antisense treated). Results were quantified by scanning
densitometry. Membrane was stripped and re-probed with b-actin antibody to verify equal protein loading, * p,0.05 compared with respective
controls. Western blot analysis of tumor tissue lysates: Mechanistic basis for the tumor growth inhibition by RLIP76-antisense was determined in the
tumor lysates from control and RLIP76-antisense treated mice. Tumor tissues were homogenized, and ,70 mg protein was resolved on SDS-PAGE and
probed for pPI3K, PI3K, pAkt, Akt, PCNA, Bim, E-cadherin, Cyclin B1 and CDK4. The blots were stripped and reprobed for GAPDH to ensure equal
protein loading (panel C). Bar diagram represents densitometry analyses. Dotted line represents no significant change as observed with scrambled
antisense (panel D).
doi:10.1371/journal.pone.0034582.g003
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RLIP76 enriched cells are resistant to radiation toxicity.
Discussion
RLIP76 is a major glutathione-conjugate transporter frequently
over-expressed in cancer cells, and is strongly linked with
resistance to apoptotic effects of a very wide variety of chemical
as well as radiation induced oxidative stress [19–26]. In the current
studies, we characterized that RLIP76 protein expression and
specific activity for transport are relatively high in pancreatic
cancer cells than non-malignant cells. Our present studies focused
on elucidation of the role of RLIP76 in the regulation of critical
survival signaling pathways prominently active in therapy resistant
pancreatic cancers. Targeting RLIP76 is also a quite unique
strategy because to date, there are no other targeting modalities
that show such a broad spectrum of activity (lung, colon, prostate,
kidney, melanoma, neuroblastoma, and pancreas) in both cell
cultures and animal models, with inherent cancer specificity [22–
24,34,48]. The significant feature of the present study was that
depletion of RLIP76 effectively targeted the activation of PI3K/
Akt pathway. Loss of E-cadherin alters the natures of cell contacts
and given the highly metastatic and aggressive nature of
pancreatic cancer, the over-expression of E-cadherin following
RLIP76 depletion is a salient factor as it is a marker which
Figure 4. Effect of anti-RLIP76 IgG, RLIP76 siRNA and RLIP76 antisense on the size of subcutaneously implanted human pancreatic
cancer cells (BxPC-3) in nude mice. Hsd: Athymic nude nu/nu mice were obtained from Harlan, Indianapolis, IN. All animal experiments were
carried out in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC). Thirty-six 11-weeks-old mice were
divided into six groups of 6 animals (treatment with pre-immune serum, scrambled siRNA, scrambled anti-sense DNA, RLIP76 antibodies, RLIP76
siRNA and RLIP76 antisense). All 36 animals were injected with 2610
6 human pancreatic cancer cells suspensions in 100 ml of PBS, subcutaneously
into one flank of each nu/nu nude mouse. Animals were examined daily for signs of tumor growth. When tumors reached a cross-sectional area of
,42 mm
2 (47 days later), animals were randomized treatment groups as indicated in the figure. Treatment consisted of 200 mg of RLIP76 antibodies,
siRNA or antisense in 100 ml PBS. Control groups were treated with 200 mg/100 ml pre-immune serum, scrambled siRNA or scrambled anti-sense DNA.
Tumors were measured in two dimensions using calipers. Photographs of animals were taken at day 1, day 10, day 20, day 40 and day 80 after
treatment are shown for all groups. Photographs of tumors were also taken at day 1 and day 47 after treatment.
doi:10.1371/journal.pone.0034582.g004
Table 2. RLIP76 transport activity in human normal and
pancreatic cancer cells.
Transport activity
(pmol/min/mg protein)
14C-DOX
3H-DNP-SG
Nonmalignant
HUVEC (umbilical endothelial) 28641 0 1 68
Malignant
BxPC-3 144612 681648
Panc-1 131610 611652
For transport studies, in-side out vesicles (IOVs) prepared from 20610
6 cells was
enriched for IOVs by wheat germ agglutinin affinity chromatography [26].
Transport activity was calculated from measurements of uptake of
14C-DOX (sp.
activity, 8.5610
4 cpm/nmol) and
3H-DNP-SG (sp. activity, 3.6610
3 cpm/nmol)
into the IOVs (20 mg/30 ml reaction mixture) in the absence or presence of
4 mM ATP as described [26]. Each transport experiment was done in triplicates
in three separate experiments (n=9).
doi:10.1371/journal.pone.0034582.t002
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pancreatic cancers [49,50]. Also, the decreased activation of
PI3K, Akt and attenuated expression of Akt, anti-apoptoticBcl2,
CDK4 along with a parallel increase in pro-apoptotic Bim provide
a collective rationale for the effective regulation of PI3K/Akt
pathway following RLIP76 depletion (Fig. 6).
RLIP76 serves as a functional nexus between glutathione
mediated defense mechanisms and predominant survival signaling
pathways in pancreatic cancer. RLIP76 represents a unique target
in cancer therapy because it functions as the rate regulatory step in
both mercapturic acid pathway as well as endocytosis [16,19,25].
The former is crucial for the protection of cells from stressors
Figure 5. RLIP76 mediated DOX transport and radiation-protection in pancreatic cancer cells. The crude membrane vesicles (inside-out
vesicles, IOV) from BxPC3 cells were separately coated with 40 mg/ml final concentration of either anti-RLIP76 IgG, anti-MRP1 IgG, or anti-Pgp IgG and
used to measure the ATP-dependent uptake of
14C-DOX. ATP-dependent uptake of
14C-DOX was determined by subtracting the radio-activity (cpm)
of the controls without ATP from that of the experimental groups containing ATP (panel A). Approximately, 2.5610
3 BxPC3 cells grown in RPMI-1640
medium, were treated with control and RLIP76-liposomes (50 mg/ml final concentration) for 24 h prior to radiation at 100, 200, 500 and 1000 cGY (6
MeV photons). After 7 days, cells were stained with methylene-blue and the colonies were counted using Alpha Imager HP [32,33] (panel B)*
p,0.05, ** p,0.01 compared to controls. The fold change in the radiation-resistance of RLIP76 vs. control-liposome treated pancreatic cancer cells at
each dose of irradiation is represented in the bar diagram (panel C). The results presented are the mean and s.d. from three separate experiments
(n=9) * p,0.05, ** p,0.01 compared to control.
doi:10.1371/journal.pone.0034582.g005
Figure 6. Major mechanisms contributing to RLIP76-mediated anti-cancer effects and chemo-radiotherapy resistance in pancreatic
cancer. RLIP76 depletion leads to predominant inhibition of PI3K/Akt pathway as revealed by the inhibition of PI3K as well as decrease in the levels
and phosphorylation of Akt. The associated downstream proteins that regulate differentiation, proliferation and apoptosis like E-cadherin, Bim, Bcl2
and CDK4 are also differentially regulated due to RLIP76 targeted interventions. The collective impact of RLIP76 depletion on the regulation of cellular
signaling pathways as well as detoxification of glutathione-conjugates (GS-Es) of lipid peroxidation and chemotherapy drugs represents precious
opportunities for the development of novel and effective therapeutic interventions for pancreatic cancers. Green arrow: Up regulation following
RLIP76 depletion; Red arrow: down regulation following RLIP76 depletion; Blue arrow: Normal signal transduction.
doi:10.1371/journal.pone.0034582.g006
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serves as a master regulator of receptor-ligand signaling. RLIP76
depletion by antisense has been shown to be safe in animal studies
and current studies reveal the potential of RLIP76 targeted
therapy to cause effective regression of pancreatic cancer. The
applications of knowledge gained from present studies could
include the optimization of combinations of other developing
drugs for targeted therapy and improving the efficacy of available
targeting agents.
The effective targets for cancer therapy must be desirably
expressed differentially in particular cancers as compared with
normal cells. Also, there should be an essential dependence of
cancer cells on the target compared to non-malignant cells.
Ideally, the target should be understood in the context of existing
biochemical and signaling frameworks known to play a direct role
in a particular carcinogenesis or in regulating the response to
therapy. Results from our present studies provide strong support
for the role of enhanced expression and function of RLIP76 in
pancreatic cancers compared to normal cells. Thus, this study also
lays a strong foundation for further clinical studies on the role of
RLIP76 in pancreatic cancers. In conclusion, these findings from
the present study regarding the role of RLIP76 in survival and
chemo-radiotherapy resistance of pancreatic cancer can poten-
tially impact the translational research for the development of
more effective and targeted therapeutic strategies for pancreatic
cancer.
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